Home » BIOCON, NOBEX CORP TIE UP FOR CARDIOVASCULAR DRUG
BIOCON, NOBEX CORP TIE UP FOR CARDIOVASCULAR DRUG
Biotechnology firm Biocon Ltd. said on Tuesday it has tied up with U.S.-based Nobex Corporation to develop an oral peptide product to treat cardiovascular diseases. Bangalore-based Biocon said in a statement the two companies planned to make an investigational new drug filing for the oral human brain-type natriuretic peptide in 2007 and start clinical trials later that year.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct